Abstract: The flameless heater system includes an energy source comprising a diesel engine configured to create volumes of air, a hydraulic system to control engine loading for heat generation and for air moving, and a control system, operatively coupled with the energy source and the hydraulic system to control at least one of a speed of the diesel engine, a loading of the diesel engine, or a fan speed.

Abstract: Alpha(v) beta (6) integrin (avb6) binding polypeptides are disclosed herein, and their use in treating and detecting tumors, and their use in treating pulmonary fibrosis.

Abstract: Gaming systems and methods that enables the exchange of monetary currency for a greater amount of virtual currency based on a first exchange rate for use by a player via the gaming system, and the exchange of virtual currency back to monetary currency based on second and third exchange rates, and in certain instances with a virtual currency usage fee. In various embodiments, the first exchange rate, the second exchange rate, the third exchange rate, and/or the virtual currency usage fee may vary based on one or more different factors such as but not limited to casino driven factors.

Abstract: Gaming systems and methods that enables the exchange of monetary currency for a greater amount of virtual currency based on a first exchange rate for use by a player via the gaming system, and the exchange of virtual currency back to monetary currency based on second and third exchange rates, and in certain instances with a virtual currency usage fee. In various embodiments, the first exchange rate, the second exchange rate, the third exchange rate, and/or the virtual currency usage fee may vary based on one or more different factors such as but not limited to casino driven factors.

Abstract: Gaming systems and methods that enables the exchange of monetary currency for a greater amount of virtual currency based on a first exchange rate for use by a player via the gaming system, and the exchange of virtual currency back to monetary currency based on second and third exchange rates, and in certain instances with a virtual currency usage fee. In various embodiments, the first exchange rate, the second exchange rate, the third exchange rate, and/or the virtual currency usage fee may vary based on one or more different factors such as but not limited to casino driven factors.

Abstract: Gaming systems and methods that enables the exchange of monetary currency for a greater amount of virtual currency based on a first exchange rate for use by a player via the gaming system, and the exchange of virtual currency back to monetary currency based on second and third exchange rates, and in certain instances with a virtual currency usage fee. In various embodiments, the first exchange rate, the second exchange rate, the third exchange rate, and/or the virtual currency usage fee may vary based on one or more different factors such as but not limited to casino driven factors.

Abstract: The flameless heater system includes an energy source comprising a diesel engine configured to create volumes of air, a hydraulic system to control engine loading for heat generation and for air moving, and a control system, operatively coupled with the energy source and the hydraulic system to control at least one of a speed of the diesel engine, a loading of the diesel engine, or a fan speed.

Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.

Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.

Abstract: This invention relates to compositions and methods for eliciting an immune response against a parasite of the genus Plasmodium in a mammal.

Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.

Abstract: The methods and compositions described herein are based, in part, on the discovery that the introduction of a disulfide bond into an integrin polypeptide by the substitution of at least one cysteine residue in the polypeptide permits stabilization of the integrin in a “closed/inactive” state. This stabilizing disulfide bond permits integrins to be screened for a candidate molecule that can bind to the closed state. In particular, this approach can be used to screen for agents that bind to the closed state of an integrin polypeptide, and are useful as therapeutic treatments to prevent integrin activation.

Abstract: Embodiments of the invention herein relate to methods of studying binding interactions between two entities and methods for screening of modulators of such binding interactions, in particular, the protein-protein interaction observed in receptor-ligand interactions.

Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1 ”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.

Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where crysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.

Abstract: The present invention provides an isolated polypeptide capable of binding to aCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a method for inhibiting ICAM-I and a pharmaceutical composition comprising an integrin (XL I domain polypeptide or biologically active portion of the polypeptides. The invention also provides a method of treating or preventing an LFA-I mediated ICAM-1 associated disease such as inflammation, artherosclerosis, allograft rejection, diabetes, T-cell mediated sensitization reaction, psoriasis, HIV infection, or rheumatoid arthritis.

Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.

Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.

Abstract: The present invention provides a method for stabilizing a protein in a desired conformation by introducing at least one disulfide bond into the polypeptide. Computational design is used to identify positions where cysteine residues can be introduced to form a disulfide bond in only one protein conformation, and therefore lock the protein in a given conformation. Accordingly, antibody and small molecule therapeutics are selected that are specific for the desired protein conformation. The invention also provides modified integrin I-domain polypeptides that are stabilized in a desired conformation. The invention further provides screening assays and therapeutic methods utilizing the modified integrin I-domains of the invention.